Lixte Biotechnology Holdings, Inc.
LIXT
$3.46
$0.1655.02%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -10.55% | -27.40% | -34.00% | -30.29% | -35.74% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -23.23% | -26.89% | -40.20% | -3.99% | -39.57% |
| Operating Income | 23.23% | 26.89% | 40.20% | 3.99% | 39.57% |
| Income Before Tax | 23.27% | 26.94% | 40.16% | 3.22% | 39.41% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 23.27% | 26.94% | 40.16% | 3.22% | 39.41% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 23.27% | 26.94% | 40.16% | 3.22% | 39.41% |
| EBIT | 23.23% | 26.89% | 40.20% | 3.99% | 39.57% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 36.56% | 33.51% | 40.07% | 10.71% | 55.12% |
| Normalized Basic EPS | 36.56% | 33.53% | 40.08% | 10.72% | 55.12% |
| EPS Diluted | 36.56% | 33.51% | 40.07% | 10.71% | 55.12% |
| Normalized Diluted EPS | 36.56% | 33.53% | 40.08% | 10.72% | 55.12% |
| Average Basic Shares Outstanding | 20.95% | 9.88% | -0.16% | 8.41% | 35.01% |
| Average Diluted Shares Outstanding | 20.95% | 9.88% | -0.16% | 8.41% | 35.01% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |